Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial: Original Research

Left atrial appendage closure with the AnchorMan or Watchman devices: 12-month results of the SAFE-PROTECT randomised trial: Original Research

In this episode of Editor's Choice, Dr Aaysha Cader speaks with Professor Huimin Chu about LAAC with AnchorMan versus Watchman 2.5 devices. They discuss how the 12-month results of the SAFE-PROTECT trial indicated the non-inferiority of the novel AnchorMan occluder for both primary and secondary endpoints: clinical success and LAA closure success at 1 year. This study found that the AnchorMan’s design, intended to improve sealing, resulted in significantly lower peridevice leak ≥3 mm compared to Watchman 2.5. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

Door-to-unload time and mortality in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock: Original Research

In this episode of Editor's Choice, Doctor Aaysha Cader speaks with Doctor Shin Nagai and Professor Toyoaki Murohara about the connection between door-to-unload time and mortality in STEMI-CS patients. They discuss how the J-PVAD registry data confirm that early unloading and prompt revascularisation are paramount; as high-volume centres achieve these targets more consistently, organised shock systems of care, such as hub-and-spoke models, appear invaluable. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

TAVI and coronary interventions: indications, technical considerations, and clinical scenarios: State-of-the-Art

In this episode of Editor's Choice, Doctor Aaysha Cader speaks with Professor Giuseppe Tarantini about the current state-of-the-art on TAVI and coronary interventions, recently published in EuroIntervention. Professor Tarantini shares insights on managing the complex interaction between CAD, PCI, and TAVI; the value of CT imaging and angiography in strategy planning; and how to optimise outcomes in different clinical scenarios. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

Glucocorticoids to reduce PPI after TAVI: the GLUCO-TAVI randomised trial: Original Research

In this episode of Editor’s Choice, Dr Aaysha Cader speaks with Dr Juan Miguel Ruiz-Nodar about the results of the GLUCO-TAVI trial, recently published in EuroIntervention. They discuss the impact of glucocorticoid therapy on reducing permanent pacemaker implantation (PPI) following TAVI, highlighting a 50% relative risk reduction at one month. Dr Ruiz-Nodar also shares insights into the mechanisms behind these findings and outlines plans for a larger randomised trial to confirm the results and define optimal dosing and treatment duration. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.

QFR versus FFR in the 2-year follow-up of FAVOR III Europe: Original Research

In this episode of Editor’s Choice, Dr Aaysha Cader speaks with Doctor Birgitte Andersen about the latest findings from the FAVOR III Europe trial, recently published in EuroIntervention. They discuss the 2-year follow-up comparing quantitative flow ratio (QFR) and fractional flow reserve (FFR), including the key outcome that QFR did not demonstrate non-inferiority at one year. Dr Andersen explores potential explanations, including concerns around reproducibility and early event rate differences, and highlights the need for further research to identify patient populations best suited for angiography-based physiological assessment. ---------------------------------------- Hosted on Acast. See acast.com/privacy [https://acast.com/privacy] for more information.